» Articles » PMID: 19372561

Alterations in the Noxa/Mcl-1 Axis Determine Sensitivity of Small Cell Lung Cancer to the BH3 Mimetic ABT-737

Overview
Journal Mol Cancer Ther
Date 2009 Apr 18
PMID 19372561
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

To understand the molecular basis for variable sensitivity to the BH3 mimetic drug ABT-737, the abundance of Bcl-2 family members was assayed in a panel of small cell lung cancer cell lines whose sensitivity varied over a 2-log range. Elevated Noxa and Bcl-2 levels directly correlated with sensitivity to ABT-737, whereas Mcl-1 levels were similar in all cell lines tested regardless of sensitivity. Transgenically enforced expression of Noxa but not Bcl-2 resulted in increased sensitivity to ABT-737 in multiple cell lines. This increase was especially pronounced in the H209 cell line in which expression of Noxa resulted in a proportionate decline in Mcl-1 expression. Although overexpression of Noxa enhanced sensitivity of the H526 and H82 cell lines to ABT-737, it did not result in altered Mcl-1 levels. Similarly, small interfering RNA-mediated knockdown of Noxa expression in the H146 cell line, which increased resistance to ABT-737, did not result in altered Mcl-1 levels. Therefore, three of four cell lines studied failed to show Noxa-mediated regulation of Mcl-1 expression. However, despite failure to regulate Mcl-1 levels, Noxa blocked binding of Bim to Mcl-1 following its release from Bcl-2 by ABT-737. Finally, we observed that a 24-hour incubation of the H526 and WBA cell lines with ABT-737 resulted in increased Noxa expression, suggesting that Noxa may play a direct role in ABT-737-mediated apoptosis. These results indicate that Noxa expression is the critical determinant of ABT-737 sensitivity and loss of Noxa-mediated regulation of Mcl-1 expression may be an important feature of small cell lung cancer biology.

Citing Articles

Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.

Alam M, Alam S, Shamsi A, Adnan M, Elasbali A, Abu Al-Soud W Front Oncol. 2022; 12:869672.

PMID: 35402265 PMC: 8990771. DOI: 10.3389/fonc.2022.869672.


BH3-mimetics: recent developments in cancer therapy.

Townsend P, Kozhevnikova M, Cexus O, Zamyatnin Jr A, Soond S J Exp Clin Cancer Res. 2021; 40(1):355.

PMID: 34753495 PMC: 8576916. DOI: 10.1186/s13046-021-02157-5.


Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.

Innao V, Rizzo V, Allegra A, Musolino C, Allegra A Cells. 2021; 10(2).

PMID: 33669515 PMC: 7922387. DOI: 10.3390/cells10020439.


Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib.

Florent R, Weiswald L, Lambert B, Brotin E, Abeilard E, Louis M Cell Death Dis. 2020; 11(5):380.

PMID: 32424251 PMC: 7235085. DOI: 10.1038/s41419-020-2588-8.


(3)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one inhibited osteosarcoma growth by inducing apoptosis.

Song M, Zhang F, Lin L Exp Ther Med. 2019; 18(2):1107-1114.

PMID: 31316606 PMC: 6601140. DOI: 10.3892/etm.2019.7681.